O Tanweer1, E Raz2, A Brunswick1, D Zumofen3, M Shapiro2, H A Riina2, M Fouladvand4, T Becske5, P K Nelson6. 1. From the Departments of Neurosurgery (O.T., A.B., D.Z., P.K.N.). 2. Radiology (E.R., D.Z., M.S., H.A.R., T.B., P.K.N.). 3. From the Departments of Neurosurgery (O.T., A.B., D.Z., P.K.N.) Radiology (E.R., D.Z., M.S., H.A.R., T.B., P.K.N.). 4. Neurology (M.F., T.B., P.K.N.), New York University School of Medicine, New York, New York. 5. Radiology (E.R., D.Z., M.S., H.A.R., T.B., P.K.N.) Neurology (M.F., T.B., P.K.N.), New York University School of Medicine, New York, New York. 6. From the Departments of Neurosurgery (O.T., A.B., D.Z., P.K.N.) Radiology (E.R., D.Z., M.S., H.A.R., T.B., P.K.N.) Neurology (M.F., T.B., P.K.N.), New York University School of Medicine, New York, New York. peter.nelson@nyumc.org.
Abstract
BACKGROUND AND PURPOSE: Recent techniques of endoluminal reconstruction with flow-diverting stents have not been incorporated into treatment algorithms for cavernous carotid aneurysms. This study examines the authors' institutional experience and a systematic review of the literature for outcomes and complications using the Pipeline Embolization Device in unruptured cavernous carotid aneurysms. MATERIALS AND METHODS: A retrospective search for cavernous carotid aneurysms from a prospectively collected data base of aneurysms treated with the Pipeline Embolization Device at our institution was performed. Baseline demographic, clinical, and laboratory values; intrainterventional data; and data at all follow-up visits were collected. A systematic review of the literature for complication data was performed with inquiries sent when clarification of data was needed. RESULTS: Forty-three cavernous carotid aneurysms were included in the study. Our mean radiographic follow-up was 2.05 years. On last follow-up, 88.4% of the aneurysms treated had complete or near-complete occlusion. Aneurysm complete or near-complete occlusion rates at 6 months, 12 months, and 36 months were 81.4%, 89.7%, and 100%, respectively. Of patients with neuro-ophthalmologic deficits on presentation, 84.2% had improvement in their visual symptoms. Overall, we had a 0% mortality rate and a 2.3% major neurologic complication rate. Our systematic review of the literature yielded 227 cavernous carotid aneurysms treated with the Pipeline Embolization Device with mortality and morbidity rates of 0.4% and 3.1%, respectively. CONCLUSIONS: Endoluminal reconstruction with flow diversion for large unruptured cavernous carotid aneurysms can yield high efficacy with low complications. Further long-term data will be helpful in assessing the durability of the cure; however, we advocate a revisiting of current management paradigms for cavernous carotid aneurysms.
BACKGROUND AND PURPOSE: Recent techniques of endoluminal reconstruction with flow-diverting stents have not been incorporated into treatment algorithms for cavernous carotid aneurysms. This study examines the authors' institutional experience and a systematic review of the literature for outcomes and complications using the Pipeline Embolization Device in unruptured cavernous carotid aneurysms. MATERIALS AND METHODS: A retrospective search for cavernous carotid aneurysms from a prospectively collected data base of aneurysms treated with the Pipeline Embolization Device at our institution was performed. Baseline demographic, clinical, and laboratory values; intrainterventional data; and data at all follow-up visits were collected. A systematic review of the literature for complication data was performed with inquiries sent when clarification of data was needed. RESULTS: Forty-three cavernous carotid aneurysms were included in the study. Our mean radiographic follow-up was 2.05 years. On last follow-up, 88.4% of the aneurysms treated had complete or near-complete occlusion. Aneurysm complete or near-complete occlusion rates at 6 months, 12 months, and 36 months were 81.4%, 89.7%, and 100%, respectively. Of patients with neuro-ophthalmologic deficits on presentation, 84.2% had improvement in their visual symptoms. Overall, we had a 0% mortality rate and a 2.3% major neurologic complication rate. Our systematic review of the literature yielded 227 cavernous carotid aneurysms treated with the Pipeline Embolization Device with mortality and morbidity rates of 0.4% and 3.1%, respectively. CONCLUSIONS: Endoluminal reconstruction with flow diversion for large unruptured cavernous carotid aneurysms can yield high efficacy with low complications. Further long-term data will be helpful in assessing the durability of the cure; however, we advocate a revisiting of current management paradigms for cavernous carotid aneurysms.
Authors: J Berge; A Biondi; P Machi; H Brunel; L Pierot; J Gabrillargues; K Kadziolka; X Barreau; V Dousset; A Bonafé Journal: AJNR Am J Neuroradiol Date: 2012-02-02 Impact factor: 3.825
Authors: Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson Journal: Radiology Date: 2013-02-15 Impact factor: 11.105
Authors: Francisco A Ponce; Felipe C Albuquerque; Cameron G McDougall; Patrick P Han; Joseph M Zabramski; Robert F Spetzler Journal: Neurosurg Focus Date: 2004-11-15 Impact factor: 4.047
Authors: R S Bechan; C B Majoie; M E Sprengers; J P Peluso; M Sluzewski; W J van Rooij Journal: AJNR Am J Neuroradiol Date: 2015-08-20 Impact factor: 3.825
Authors: Mehdi Abbasi; Luis E Savasatano; Waleed Brinjikji; Kevin M Kallmes; Nick Mikoff; Natalie Reierson; Mohamed Abdelmegeed; John Pederson; Beth Warren; Jillienne C Touchette; Sarah Khan; Shelby Kamrowski; Averi Barrett; David F Kallmes; Ramanathan Kadirvel Journal: Interv Neuroradiol Date: 2021-06-22 Impact factor: 1.764